Highest-materiality recent filing
Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance
Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.
Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M
Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.
Xtant Medical secures exclusive U.S. distribution rights for HEMOBLAST Bellows hemostat
Paid Dilon a $5.0M exclusivity fee; no minimum purchase requirements.
Xtant Medical reports FY2025 net income $5.0M vs loss $16.5M; revenue $134M (+14% YoY)
Full-year 2025 revenue $134.0M (+14% YoY); net income $5.0M ($0.03 diluted EPS) vs net loss $16.5M in 2024.
Received $10.7M on Feb 27, 2026 from Companion Spine: full repayment of $8.2M note plus accrued interest and working capital adjustments.
Xtant completes sale of Coflex/CoFix and Paradigm OUS to Companion Spine for $19.2M
Total consideration $19.2M: $11.0M cash plus $8.2M unsecured promissory note maturing Jan 15, 2026.
XTNT stockholders approve 12.3M share increase to 2023 equity plan at annual meeting
12,300,000 additional shares approved for 2023 Equity Incentive Plan, effective immediately.
Xtant Medical Q3 revenue $33.3M (+19% YoY); net income $1.3M vs loss
Revenue $33.3M (19% YoY); gross margin 66.1% vs 58.4%; net income $1.3M ($0.01 EPS) vs loss $5.0M (-$0.04 EPS).
Xtant Medical Q2 2025 revenue $35.4M (+18% YoY), net income $3.6M, raises FY guidance
Revenue $35.4M up 18% YoY; gross margin improved to 68.6% from 62.1%.
Xtant sells Coflex/CoFix and OUS businesses to Companion Spine for $19.2M
Total consideration $19.2M: $11M cash at close plus $8.2M promissory note due Dec. 31, 2025.
Xtant Medical Q1 revenue $32.9M (+18% YoY), net income $58K, raises FY2025 guidance to $127-131M
Revenue $32.9M, up 18% vs Q1 2024; net income $58K vs net loss $4.4M prior year.
OrbiMed affiliates sold 73.1M shares (52.5% of outstanding) to Nantahala-led group at $0.42/share; OrbiMed now holds no Xtant shares.
OrbiMed affiliates sell ~73.1M Xtant shares at $0.42 to Nantahala; Nantahala to own 49.1%
OrbiMed affiliates selling 73.1M shares (all their XTNT shares) to Nantahala and other purchasers at $0.42/share.
Xtant Medical reports 28% revenue growth in FY2024; guides FY2025 revenue $126M-$130M
Revenue $117.3M FY2024, up 28% YoY; Q4 revenue $31.5M, up 12%.
Xtant Medical Q3 revenue $27.9M (+12% YoY); reaffirms FY2024 guidance $116-120M
Revenue $27.9M (+12% YoY); YTD revenue $85.8M (+36% YoY).
Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M
Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.
Xtant Medical raises $5.0M via private placement of 7.8M shares at $0.64/share
Gross proceeds of $5.0M from sale of 7,812,500 shares at $0.64/share to existing institutional investor.
Xtant Medical Q1 revenue up 55% to $27.9M; raises FY2024 revenue guidance to $116M-$120M
Revenue of $27.9M, up 55% YoY from $17.9M.
Xtant Medical reports record FY 2023 revenue $91.3M, up 58% YoY; guides FY 2024 $112M-$116M
FY 2023 revenue $91.3M, +58% YoY; organic growth 15%.
Xtant Medical upsizes revolver to $17M, extends maturity to 2029, removes EBITDA covenant
Revolving credit facility increased from $8M to $17M with MidCap Financial.
Xtant Medical reports record Q3 revenue of $25M, raises FY2023 guidance to $88M-$91M
Revenue $25.0M, +73% YoY; organic growth 18%; acquisition contributions 55%.
Surgalign Q1 2023 revenue $16.7M (down 19% YoY); net income $4.1M included $12.6M gain on Coflex sale.
Xtant Medical completes acquisition of Surgalign's hardware and biologics business for $5 million
Xtant Medical acquired certain assets of Surgalign Holdings, Inc. for $5 million cash plus assumed liabilities under Bankruptcy Court supervision.
Xtant Medical Q2 revenue up 32% to $20.2M; raises FY 2023 guidance to $75-77M
Revenue $20.2M, up 32% YoY (14% organic, 18% from Coflex/CoFix acquisition).
Xtant Medical wins auction for Surgalign's biologics and spinal fixation assets
Won auction for Surgalign's domestic and international biologics and spinal fixation assets via initial bid from June 18 APA.
Private placement of 20M shares at $0.75/share for gross proceeds of $15M.
Xtant completes $17M acquisition of Surgalign SPV's Coflex/CoFix product lines
Purchase price $17M in cash; funded with cash on hand and $5M from existing term loan.
Xtant Medical Q1 revenue up 38% to $17.9M; initiates FY2023 guidance $73-75M
Q1 2023 revenue of $17.9M, up 38% YoY (29% organic, 9% from Coflex acquisition).
Xtant Medical Q4 revenue up 9% to $15.3M; full year net loss widens to $8.5M
Q4 revenue $15.3M, up 9% YoY; full year revenue $58.0M, up 5% YoY.
Xtant Medical acquires Coflex product line from Surgalign for $17M cash
Acquired Coflex and CoFix product lines from Surgalign for $17M cash; closed Feb 28, 2023.
On May 16, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Lori D. Mitchell-Keller to the Board, effective immediately.
Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.
Michael Eggenberg and Matthew Rizzo resigned as directors of the Company, effective immediately upon the date in which the Board elected Jonn R. Beeson as a director.
On May 1, 2023, the Board of Directors (the “Board”) of Xtant Medical Holdings, Inc. (the “Company”) elected Jonn R. Beeson to the Board, effective immediately.
On January 9, 2023, Xtant Medical Holdings, Inc. (the “Company”) announced the appointment of Mark A. Schallenberger as Chief Operations Officer, effective as of January 16, 2023.
the Board elected Mr. Vizirgianakis as Chairman of the Board, effective upon completion of the First Closing, to replace Jeffrey Peters, who previously served as Chairman of the Board and intends not to stand for re-election at the Company’s next annual meeting of stockholders
the Board elected Mr. Vizirgianakis as Chairman of the Board, effective upon completion of the First Closing, to replace Jeffrey Peters, who previously served as Chairman of the Board and intends not to stand for re-election at the Company’s next annual meeting of stockholders
to replace Jeffrey Peters, who is currently serving as Chairman of the Board and intends not to stand for re-election at the Company's next annual meeting of stockholders
On April 27, 2022, the Board of Directors of Xtant Medical Holdings, Inc. (the “Company”) approved the appointment of Scott C. Neils as non-interim Chief Financial Officer, effective June 1, 2022.
announced the appointment of Scott Neils as Interim Chief Financial Officer
whose employment terminated effective as of January 3, 2022.
Max materiality 0.90 · Median 0.65 · Most common event earnings